Alpha Tau Medical Ltd. (NASDAQ:DRTS)
| Market Cap | $1.09B+222.1% |
| Revenue (ttm) | $0 |
| Net Income | -$111.04M-177.8% |
| EPS | -$1.22-130.2% |
| Shares Out | 92.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 628,875 |
| Open | $11.52 |
| Previous Close | $11.31 |
| Day's Range | $11.39 - $12.04 |
| 52-Week Range | $3.65 - $15.79 |
| Beta | 1.29 |
| Analysts | Buy |
| Price Target | $23.00(+95.66%) |
| Earnings Date | Mar 8, 2027 |
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating DRTS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 8, 2027Earnings report
$DRTS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in DRTS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DRTS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DRTS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New DRTS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DRTS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DRTS
| IEFAiShares Core MSCI EAFE ETF | $5.56M |
| SCZiShares MSCI EAFE Small-Cap ETF | $2.62M |
| EISiShares MSCI Israel ETF | $1.56M |
| IZRLARK Israel Innovative Technology ETF | $1.53M |
| IXUSiShares Core MSCI Total International Stock ETF | $744.43K |
| GWXState Street SPDR S&P International Small Cap ETF | $440.34K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from DRTS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Positive interim trial results with 100% ORR, analyst upgrade from Piper Sandler to Overweight, and successful trial endpoints justify bullish sentiment.
